A. Forjaz de Lacerda

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.

Ruth Ladenstein, Adela Cañete, Victoria Castel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

M. Garami, I. Yaniv, T. Trahair, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

M. Garami, I. Yaniv, T. Trahair, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.

K. McHugh, M. Gaze, P. Ambros, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trends in cause and place of death for children in Portugal (a European country with no Paediatric palliative care) during 1987–2011: a population-based study

B. Gomes, A. Forjaz de Lacerda, 2017, BMC Pediatrics.